Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center discussing results from AIM’s Phase 2 study evaluating the efficacy and safety of Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue